May 28, 2026 8:33 AM
From Biologics to Gene Therapy: A Conversation with Jim McNally
Date: May 2026
Participants: Jim McNally (Chief Scientific Officer, Sword Bio), Carolina Molecular Team
Overview
Carolina Molecular recently sat down with Jim McNally of Sword Bio to discuss his path from the Gulf Coast of Mississippi into biotech and drug development, the evolution of CRO partnerships, and the increasing complexity of modern therapeutics.
Throughout the conversation, Jim shares perspectives shaped by years of experience across academia, pharma, biotech, and CRO leadership — including work in biologics, pharmacokinetics and pharmacodynamics, gene therapy, and regulated bioanalytical development. The discussion also explores how multi-omics, molecular tools, and emerging therapeutic modalities are reshaping the future of clinical development and personalized medicine.
From Mississippi to New England: Finding a Path Into Science
Jason: To begin, could you share where you grew up and a bit about your early background?
Jim: I’m a southerner, originally from the Gulf Coast of Mississippi. I spent the first 21 years of my life there. I attended Mississippi State University for my undergraduate degree and later went on to LSU Medical Center for graduate school.
Jason: What first sparked your interest in science?
Jim: I’ve had an interest in science for as long as I can remember, going back to junior high and high school. I enjoyed learning and exploring how things worked.
My path into the field was somewhat indirect. I initially intended to study biomedical engineering. During my first couple of years at Mississippi State, I did well in biology courses but struggled with engineering.
I had always imagined the two would be the perfect combination for me — I loved science and I liked math — but I quickly realized I was far more engaged by biology. Math was more of a tool than an interest.
A professor noticed my performance and suggested I consider focusing on biology and possibly pursuing graduate school. He connected me with a colleague at LSU Medical Center, which ultimately set me on that path.
At the time, I didn’t realize how pivotal that decision would be. I’ve found a great deal of fulfillment in the field. While it may not have been a carefully mapped plan, I followed what I enjoyed and focused on that direction.
Transitioning From Academia Into Industry
Jason: How did you initially transition from academia into industry?
Jim: I followed a fairly typical academic path at first. I completed my PhD at LSU, and my external thesis advisor was a well-regarded scientist at UMass Medical Center in Worcester. It was standard practice to have an external reviewer for the thesis work, and that connection proved important later.
Through that interaction, I developed a professional relationship that stayed with me.
At the time, I expected to pursue a traditional academic career. My wife, whom I met during graduate school and who is also a scientist, was from New England, so we eventually relocated there to support both of our careers.
My expectation was to become a tenured professor — that was the only career path I really knew.
However, during my postdoc in New England, I was surrounded by biotech and pharmaceutical companies, which exposed me to a completely different set of opportunities.
Over time, I found myself less interested in research purely for its own sake. I wanted to be closer to the process of translating science into therapies that could actually reach patients.
That shift in perspective ultimately led me into industry, and I haven’t looked back.
The Expanding Role of CROs in Drug Development
Jason: What do you see as the key forces driving the decentralization of drug development from large in-house pharma groups to today’s CRO- and CDMO-driven ecosystem?
Jim: I tend to think about it in terms of regulated versus non-regulated work.
Within pharma and biotech, it often makes sense to keep non-GLP exploratory science in-house. That’s where teams can deeply engage with biology and conduct discovery-driven work.
However, once programs transition into GLP-regulated environments, the infrastructure required becomes difficult to justify internally unless a company has a very large and consistent pipeline.
The volume simply isn’t there for most organizations to maintain that level of investment in-house, whereas CROs can support it across many programs and clients.
Because CROs operate at scale, they can sustain the compliance infrastructure required for regulated work in a way that is economically and operationally viable.
Another important shift over the past decade is the influx of experienced drug development scientists into the CRO space. That has significantly changed the quality and perspective within these organizations.
Today, CROs are more collaborative and more aware of what works — and what doesn’t — across both scientific and regulatory contexts.
Increasing Complexity in Modern Therapeutics
Jason: Beyond the growth of CROs and new therapeutic modalities, what other major changes have you seen in clinical drug development?
Jim: The complexity of therapeutic modalities has increased substantially.
Where biologics were once primarily recombinant proteins, enzymes, or monoclonal antibodies, we now work with bi-specifics, tri-specifics, gene therapies, and cell therapies. These are not just large molecules — they are significantly more complex systems.
As a result, bioanalytical strategies have become equally sophisticated to keep pace.
At Sword Bio, for example, in collaboration with Carolina Molecular, we see both protein-level considerations and molecular biology tools becoming essential in ways that weren’t part of traditional GLP PK/PD workflows in earlier biologic programs.
The Promise of Multi-Omics and Personalized Medicine
Jason: How do you see multi-omics influencing drug development — particularly in areas like patient stratification, targeting, and PK/PD analysis?
Jim: I think there is real opportunity for improved patient targeting and better alignment of therapies to specific populations.
“Personalized medicine” is a term that has been used heavily over the past decade, but I do think we are steadily moving in that direction.
That said, progress will likely be uneven. We often solve one problem with a therapy, only to introduce new challenges that require additional interventions.
The goal is to better understand the full biological context of each patient — because most diseases are not driven by a single cause or a single pathway.
Improving how we interpret that complexity will be key to advancing truly personalized approaches.
Building a Career in Gene Therapy
Jason: You have a strong background in AAV and gene therapy. How did that experience develop?
Jim: I would say I got my start somewhat unexpectedly.
At Shire, I stepped into a global program lead role in the non-clinical space and immediately inherited several AAV gene therapy programs — despite having no prior direct experience with them.
At the time, the extent of my AAV knowledge was essentially limited to how to spell it.
It was a steep learning curve, but an incredibly formative experience.
Looking back, my career often looks like a series of unplanned steps. I didn’t initially set out to work in gene therapy, but I found myself in the space and quickly became deeply engaged.
It is one of the most exciting areas in biotherapeutic development. It shifts the conversation from treating disease to the possibility of curing it — which carries a significant sense of responsibility.
Building Something Different at Sword Bio
Jason: What most excites you about your work at Sword Bio?
Jim: Someone once pointed out to me that I tend to move roles every four to five years and consistently look for opportunities to build something new. I think that’s a fair observation.
I’ve worked with many CROs from the client side, and I’ve been fortunate to collaborate with strong teams and capable scientists throughout my career.
Now, being on the other side, I’ve gained a clearer view of how those organizations operate internally — and where there is room to improve.
At Sword Bio, we are focused on building a different model based on that experience.
How Sword Bio Approaches Scientific Partnership
Jason: How does Sword Bio differentiate itself within the CRO landscape?
Jim: One of our core principles is maintaining deep engagement from senior scientific leadership across every program.
In many traditional CRO models, senior scientists are heavily involved during business development and early engagement, but less consistently involved during execution unless issues arise.
We are intentionally structuring things differently.
At Sword Bio, senior scientists — including myself and our site leadership — remain actively engaged throughout the entire lifecycle of a project.
That means working collaboratively on method development, reviewing data on an ongoing basis, and staying closely connected to execution.
Our goal is to ensure clients have continuous senior scientific oversight, not just at the start of a project or when problems occur, but throughout the entire process.
Conclusion
As Jim noted, the evolution of drug development is defined by increasing complexity paired with the need for more precise and adaptable scientific approaches. From advanced modalities such as gene and cell therapies to the integration of molecular tools into PK/PD and bioanalytical workflows, the field continues to move beyond traditional frameworks.
At the center of this shift is a growing emphasis on collaboration — across disciplines, organizations, and scientific domains — to ensure increasingly complex data can be translated into meaningful, decision-driving insights.
Jim’s journey, from early academic interests in biology to leadership roles across biotech, pharma, and CRO environments, reflects this broader transformation in the industry.
At Carolina Molecular, we are proud to work alongside partners like Sword Bio to support this next era of development, where molecular expertise and bioanalytical innovation come together to advance increasingly complex therapeutic programs.